-
1Academic Journal
Συγγραφείς: K. N. Grigoreva, V. O. Bitsadze, A. V. Vorobev, A. G. Solopova, J. Kh. Khizroeva, A. Z. Iakubov, J. Yu. Ungiadze, I. S. Kalashnikova, D. O. Utkin, D. V. Blinov, J.-C. Gris, I. Elalamy, G. Gerotziafas, A. D. Makatsariya, К. Н. Григорьева, В. О. Бицадзе, А. В. Воробьев, А. Г. Солопова, Д. Х. Хизроева, А. З. Якубов, Д. Ю. Унгиадзе, И. С. Калашникова, Д. О. Уткин, Д. В. Блинов, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, A. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 4 (2025); 514-523 ; Акушерство, Гинекология и Репродукция; Vol 19, No 4 (2025); 514-523 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: триггеры, recurrent venous thromboembolic events, VTE, thrombophilia, antiphospholipid antibodies, aPL, von Willebrand factor, vWF, metalloprotease ADAMTS-13, thromboinflammation, endothelial dysfunction, coronavirus infection, COVID-19, risk factors, triggers, рецидивирующие венозные тромбоэмболические осложнения, ВТЭО, тромбофилия, антифосфолипидные антитела, АФА, фактор фон Виллебранда, металлопротеаза ADAMTS-13, тромбовоспаление, эндотелиальная дисфункция, коронавирусная инфекция, факторы риска
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2551/1381; Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47. https://doi.org/10.1200/JCO.2009.22.3271.; Sørensen H.T., Pedersen L., van Es N. et al. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur. 2023;34:100739. https://doi.org/10.1016/j.lanepe.2023.100739.; Bertoletti L., Madridano O., Jiménez D. et al. Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC Cardio Oncol. 2023;5(6):758–72. https://doi.org/10.1016/j.jaccao.2023.09.003.; Abu Saadeh F., Norris L., O'Toole S., Gleeson N. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):214–8. https://doi.org/10.1016/j.ejogrb.2013.06.004.; Trugilho I.A., Renni M.J.P., Medeiros G.C. et al. Incidence and factors associated with venous thromboembolism in women with gynecologic cancer. Thromb Res. 2020;185:49–54. https://doi.org/10.1016/j.thromres.2019.11.009.; Lanting V.R., Takada T., Bosch F.T.M. et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost. 2025;125(6):589–96. https://doi.org/10.1055/a-2418-3960.; van Hylckama Vlieg M.A.M., Nasserinejad K., Visser C. et al. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. EClinicalMedicine. 2023;64:102194. https://doi.org/10.1016/j.eclinm.2023.102194.; Цветовская Г.А., Чикова Е.Д., Лифшиц Г.И. Генетические факторы риска тромбофилии у женщин репродуктивного возраста в Западно-Сибирском регионе. Фундаментальные исследования. 2010;(10):72–9.; Hamidpour M., Ghorbani M., Rezaei-Tavirani M. et al. Factor V Leiden, MTHFR C677T and prothrombin gene mutation G20210A in Iranian patients with venous thrombosis. IJBC. 2019;11(3):91–5.; Costa J., Araújo A. The contribution of inherited thrombophilia to venous thromboembolism in cancer patients. Clin Appl Thromb Hemost. 2024;30:10760296241232864. https://doi.org/10.1177/10760296241232864.; Lijfering W.M., Middeldorp S., Veeger N.J. et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation. 2010;121(15):1706–12. https://doi.org/10.1161/ CIRCULATIONAHA.109.906347.; Marchiori A., Mosena L., Prins M.H., Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92(8):1107–14. https://doi.org/10.3324/haematol.10234.; Zee R.Y., Bubes V., Shrivastava S. et al. Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. Clin Chim Acta. 2009;402(1–2):189–92. https://doi.org/10.1016/j.cca.2009.01.011.; Ivanov P., Komsa-Penkova R., Kovacheva K. et al. Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences. Lung. 2008;186(1):27–36. https://doi.org/10.1007/s00408-007-9061-7.; Dicks A.B., Moussallem E., Stanbro M. et al. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J Clin Med. 2024;13(2):362. https://doi.org/10.3390/jcm13020362.; Knight J.S., Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol. 2022;44(3):347–62. https://doi.org/10.1007/s00281-022-00916-w.; Poolen G.C., Urbanus R.T., Roest M. et al. Elevated levels of (active) von Willebrand factor during anticoagulation are associated with early recurrence of venous thromboembolism. J Thromb Haemost. 2025 May 13:S1538-7836(25)00313-7. https://doi.org/10.1016/j.jtha.2025.04.030.; Jara-Palomares L., Bikdeli B., Jiménez D. et al.; RIETE Investigators. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19-associated venous thromboembolism: a prospective multicentre cohort study. EClinicalMedicine. 2024;73:102659. https://doi.org/10.1016/j.eclinm.2024.102659.; Demelo-Rodriguez P., Alonso-Beato R., Jara-Palomares L. et al.; RIETE Investigators. COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding. Res Pract Thromb Haemost. 2023;7(7):102206. https://doi.org/10.1016/j.rpth.2023.102206.; Макацария А.Д. COVID-19 и системные тромботические синдромы. Акушерство, Гинекология и Репродукция. 2024;18(6):908–18. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.590.; Воробьев А.В., Эйнуллаева С.Э., Бородулин А.С. и др. Влияние COVID-19 на тромботические осложнения у онкологических больных. Акушерство, Гинекология и Репродукция. 2024;18(3):286–99. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.519.; https://www.gynecology.su/jour/article/view/2551
-
2Academic Journal
Συγγραφείς: K. N. Grigoreva, V. O. Bitsadze, J. Kh. Khizroeva, V. I. Tsibizova, M. V. Tretyakova, D. V. Blinov, L. L. Pankratyeva, N. R. Gashimova, F. E. Yakubova, A. S. Antonova, J.-C. Gris, I. Elalamy, A. D. Makatsariya, К. Н. Григорьева, В. О. Бицадзе, Д. Х. Хизроева, В. И. Цибизова, М. В. Третьякова, Д. В. Блинов, Л. Л. Панкратьева, Н. Р. Гашимова, Ф. Э. Якубова, А. С. Антонова, Ж.-К. Гри, И. Элалами, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 16, No 5 (2022); 588-599 ; Акушерство, Гинекология и Репродукция; Vol 16, No 5 (2022); 588-599 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: система гемостаза, vWF, ADAMTS-13 metalloprotease, vWF/ADAMTS-13, von Willebrand disease, hemostasis, металлопротеаза ADAMTS-13, болезнь Виллебранда
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1465/1059; https://www.gynecology.su/jour/article/view/1465/1060; Zhou Y.-F., Eng E.T., Zhu J. et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449–58. https://doi.org/10.1182/blood-2012-01-405134.; Nightingale T., Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11 Suppl 1(Suppl 1):192–201. https://doi.org/10.1111/jth.12225.; Valentijn K.M., Sadler J.E., Valentijn J.A. et al. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033–43. https://doi.org/10.1182/blood-2010-09-267492.; Lenting P.J., Christophe O.D., Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019–28. https://doi.org/10.1182/blood-2014-06-528406.; De Ceunynck K., De Meyer S.F., Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270–7. https://doi.org/10.1182/blood-2012-07-442285.; Wieberdink R.G., van Schie M.C., Koudstaal P.J. et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–6. https://doi.org/10.1161/STROKEAHA.110.586289.; Rietveld I.M., Lijfering W.M., le Cessie S. et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost. 2019;17(1):99–109. https://doi.org/10.1111/jth.14343.; Bowman M., Hopman W.M., Rapson D. et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–6. https://doi.org/10.1111/j.1538-7836.2009.03661.x.; Von Willebrand E.A. Hereditary pseudohaemophilia. Haemophilia. 1999;5(3):223–31; discussion 222. https://doi.org/10.1046/j.1365-2516.1999.00302.x.; Verweij C.L., Diergaarde P.J., Hart M., Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8):1839–47.; Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424. https://doi.org/10.1146/annurev.biochem.67.1.395.; Mannucci P.M. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683–94. https://doi.org/10.1056/NEJMra040403.; James A.H., Kouides P.A., Abdul-Kadir R. et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124–34. https://doi.org/10.1016/j.ejogrb.2011.04.025.; Govorov I., Ekelund L., Chaireti R. et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease. Exp Ther Med. 2016;11(5):1923–9. https://doi.org/10.3892/etm.2016.3144.; Lavin M., Aguila S., Dalton N. et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784–91. https://doi.org/10.1182/bloodadvances.2018017418.; Nowak-Göttl U., Limperger V., Kenet G. et al. Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis. 2017;67:2–13. https://doi.org/10.1016/j.bcmd.2016.11.012.; James A.H., Konkle B.A., Kouides P. et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81–7. https://doi.org/10.1111/hae.12568.; James A.H., Jamison M.G. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165–9. https://doi.org/10.1111/j.1538-7836.2007.02563.x.; Majluf-Cruz K., Anguiano-Robledo L., Calzada-Mendoza C.C. et al. von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage. Haemophilia. 2020;26(1):97–105. https://doi.org/10.1111/hae.13900.; South K., Freitas M.O., Lane D.A. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J Biol Chem. 2018;293(4):1149–50. https://doi.org/10.1074/jbc.M117.776732.; Plautz W.E., Raval J.S., Dyer M.R. et al. ADAMTS13: origins, applications and prospects. Transfusion. 2018;58(10):2453–62. https://doi.org/10.1111/trf.14804.; de Groot R., Lane D.A., Crawley J.T. The role of the ADAMTS13 cysteinerich domain in VWF binding and proteolysis. Blood. 2015;125(12):1968–7. https://doi.org/10.1182/blood-2014-08-594556.; Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–8. https://doi.org/10.1182/blood-2013-04-460147.; Katneni U.K., Ibla J.C., Hunt R. et al. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period. J Thromb Haemost. 2019;17(3):429–40. https://doi.org/10.1111/jth.14374.; Schaller M., Studt J.D., Voorberg J., Kremer Hovinga J.A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013;33(2):121–30. https://doi.org/10.5482/HAMO-12-12-0023.; De Young V., Singh K., Kretz C.A. Mechanisms of ADAMTS13 regulation. J Thromb Haemost. 2022 Sep 8. https://doi.org/10.1111/jth.15873. Onlineahead of print.; Sánchez-Aranguren L.C., Prada C.E., Riaño-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014;5:372. https://doi.org/10.3389/fphys.2014.00372.; Molvarec A., Rigó J., Bõze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 2009;101(2):305–11.; Aref S., Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology. 2013;18(4):237–41. https://doi.org/10.1179/1607845412Y.0000000070.; Sánchez-Luceros A., Meschengieser S.S., Marchese C. et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis. 2003;14(7):647–5. https://doi.org/10.1097/00001721-200310000-00005.; Grandone E., Vimercati А., Sorrentino F. et al. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis. BMC Pregnancy Childbirth. 2022;22(1):142. https://doi.org/10.1186/s12884-022-04405-8.; Reiter R.A., Varadi K., Turecek P.L. et al. Changes in ADAMTS13 (vonWillebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005;93:554–8. https://doi.org/10.1160/TH04-08-0467.; Strauss T., Elisha N., Ravid B. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. 2017;67:14–7. https://doi.org/10.1016/j.bcmd.2016.12.013.; Khorana A., Francis C., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.; Palacios-Acedo A.L., Mege D., Crescence L. et al. Platelets, thromboinflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805. https://doi.org/10.3389/fimmu.2019.01805.; Mochizuki S., Soejima K., Shimoda M. et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012;104(12):906–22. https://doi.org/10.1093/jnci/djs232.; Ishihara J., Ishihara A., Starke R.D. et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood. 2019;133(24):2559–69. https://doi.org/10.1182/blood.2019000510.; Guo R., Yang J., Liu X. et al. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small cell lung cancer. J Clin Lab Anal. 2018;32(1):e22219. https://doi.org/10.1002/jcla.22219.; Koh S.C., Razvi K., Chan Y. et al. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet. 2011;284(1):183–90. https://doi.org/10.1007/s00404-010-1605-z.; Marfia G., Navone S.E., Fanizzi C. et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Med. 2016;5(8):1783–90. https://doi.org/10.1002/cam4.747.; Rho J., Ladd J.J., Li C. et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018;67(3):473–84. https://doi.org/10.1136/gutjnl-2016-312794.; Yang A.-J., Wang M., Wang Y. et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis. 2018;7(1):12. https://doi.org/10.1038/s41389-017-0023-5.; Xu Y., Pan S., Liu J. et al. GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature. Oncotarget. 2017;8(66):110517–29. https://doi.org/10.18632/oncotarget.22806.; John A., Robador J.R., Vidal-Y-Sy S. et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation. Mol Cancer Res. 2020;18(7):1099–109. https://doi.org/10.1158/1541-7786.MCR-19-1041.; Bauer A.T., Suckau J., Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153–63. https://doi.org/10.1182/blood-2014-08-595686.; O’Sullivan J.M., Preston R.J., Robson T., O’Donnell J.S. Emerging roles for von Willebrand factor in cancer cell biology. Semin Thromb Hemost. 2018;44(2):159–66. https://doi.org/10.1055/s-0037-1607352.; Suter C.M., Hogg P.J., Price J.T. et al. Identification and characterisation of a platelet GPIb/V/IX-like complex on human breast cancers: implications for the metastatic process. Jpn J Cancer Res. 2001;92(10):1082–92. https://doi.org/10.1111/j.1349-7006.2001.tb01063.x.; Yang X., Sun H., Li Z. et al. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer. 2015;15:80. https://doi.org/10.1186/s12885-015-1083-6.; Goertz L., Schneider S.W., Desch A. et al. Heparins that block VEGF-Amediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget. 2016;7(42):68527–45. https://doi.org/10.18632/oncotarget.11832.; Brill A., Fuchs T.A., Savchenko A.S. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136–44. https://doi.org/10.1111/j.1538-7836.2011.04544.x.; Staessens S., Denorme F., François O. et al. Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. Haematologica. 2020;105(2):498–507. https://doi.org/10.3324/haematol.2019.219881.; Verhenne S., Denorme F., Libbrecht S. et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood. 2015;126(14):1715–22. https://doi.org/10.1182/blood-2015-03-632901.; Sonneveld M., de Maat M.P.M., Leebeek F.W.G. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systemic review and metaanalysis. Blood Rev. 2014;28(4):167–78. https://doi.org/10.1016/j.blre.2014.04.003.; McCabe D.J., Murphy S.J., Starke R. et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015;348(1–2):35–40. https://doi.org/10.1016/j.jns.2014.10.035.; Kovacevic K.D., Mayer F.J., Jilma B. et al. Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study. Atherosclerosis. 2019;290:31–6. https://doi.org/10.1016/j.atherosclerosis.2019.09.003.; Andersson H., Siegerink B., Luken B. et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555–60. https://doi.org/10.1182/blood-2011-09-380618.; Qu L., Jiang M., Qiu W. et al. Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction. Clin Appl Thromb Hemost. 2016;22(3):252–9. https://doi.org/10.1177/1076029615583347.; Donkel S.J., Benaddi B., Dippel D.W.J. et al. Prognostic hemostasis biomarkers in acute ischemic stroke: a systematic review. Arterioscler Thromb Vasc Biol. 2019;39(3):360–72. https://doi.org/10.1161/ATVBAHA.118.312102.; Peeling R.W., Heymann D.L., Teo Y.-Y., Garcia P.J. Diagnostics for COVID19: moving from pandemic response to control. Lancet. 2022;399(10326):757–68. https://doi.org/10.1016/S0140-6736(21)02346-1.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.; Helms J., Tacquard C., Severac F. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.; Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.; Loo J., Spittle D.A., Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412–20. https://doi.org/10.1136/thoraxjnl-2020-216243.; Cordoro K.M., Reynolds S.D., Wattier R., McCalmont T.H. Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol. 2020;37(3):419–23. https://doi.org/10.1111/pde.14227.; Zuo Y., Yalavarthi S., Shi H. et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020 Apr 14;2020.04.09.20059626. https://doi.org/10.1101/2020.04.09.20059626. Preprint.; Seth R., McKinnon T.A.J., Zhang X.F. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol. 2022;322(1):H87–H93. https://doi.org/10.1152/ajpheart.00204.2021.; Favaloro E.J., Henry B.M., Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021;47(4):400–18. https://doi.org/10.1055/s-0041-1727282.; Xu X., Feng Y., Jia Y. et al. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and metaanalysis. Thromb Res. 2022;218:83–98. https://doi.org/10.1016/j.thromres.2022.08.017.; Бицадзе В.О., Хизроева Д.Х., Гри Ж.-К. и др. Патогенетическое и прогностическое значение воспаления и нарушений в оси ADAMTS13/vWF у больных тяжелой формой COVID-19. Акушерство, Гинекология и Репродукция. 2022;16(3):228–43. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.327.; https://www.gynecology.su/jour/article/view/1465